E-viri
Recenzirano
Odprti dostop
-
Buocikova, Verona; Longhin, Eleonora Marta; Pilalis, Eleftherios; Mastrokalou, Chara; Miklikova, Svetlana; Cihova, Marina; Poturnayova, Alexandra; Mackova, Katarina; Babelova, Andrea; Trnkova, Lenka; El Yamani, Naouale; Zheng, Congying; Rios-Mondragon, Ivan; Labudova, Martina; Csaderova, Lucia; Kuracinova, Kristina Mikus; Makovicky, Peter; Kucerova, Lucia; Matuskova, Miroslava; Cimpan, Mihaela Roxana; Dusinska, Maria; Babal, Pavel; Chatziioannou, Aristotelis; Gabelova, Alena; Rundén-Pran, Elise; Smolkova, Bozena
Biomedicine & pharmacotherapy, March 2022, 2022-Mar, 2022-03-00, 20220301, 2022-03-01, Letnik: 147Journal Article
Acquired drug resistance and metastasis in breast cancer (BC) are coupled with epigenetic deregulation of gene expression. Epigenetic drugs, aiming to reverse these aberrant transcriptional patterns and sensitize cancer cells to other therapies, provide a new treatment strategy for drug-resistant tumors. Here we investigated the ability of DNA methyltransferase (DNMT) inhibitor decitabine (DAC) to increase the sensitivity of BC cells to anthracycline antibiotic doxorubicin (DOX). Three cell lines representing different molecular BC subtypes, JIMT-1, MDA-MB-231 and T-47D, were used to evaluate the synergy of sequential DAC + DOX treatment in vitro. The cytotoxicity, genotoxicity, apoptosis, and migration capacity were tested in 2D and 3D cultures. Moreover, genome-wide DNA methylation and transcriptomic analyses were employed to understand the differences underlying DAC responsiveness. The ability of DAC to sensitize trastuzumab-resistant HER2-positive JIMT-1 cells to DOX was examined in vivo in an orthotopic xenograft mouse model. DAC and DOX synergistic effect was identified in all tested cell lines, with JIMT-1 cells being most sensitive to DAC. Based on the whole-genome data, we assume that the aggressive behavior of JIMT-1 cells can be related to the enrichment of epithelial-to-mesenchymal transition and stemness-associated pathways in this cell line. The four-week DAC + DOX sequential administration significantly reduced the tumor growth, DNMT1 expression, and global DNA methylation in xenograft tissues. The efficacy of combination therapy was comparable to effect of pegylated liposomal DOX, used exclusively for the treatment of metastatic BC. This work demonstrates the potential of epigenetic drugs to modulate cancer cells' sensitivity to other forms of anticancer therapy. Display omitted •Trastuzumab-resistant HER2-positive tumor cells show high sensitivity to decitabine.•Decitabine enhances doxorubicin treatment efficacy in vitro and in vivo.•Combined treatment inhibits DNMT1 expression in tumor xenografts.•Decrease in tumor weight is accompanied by lowered global DNA methylation level.•Efficacy of combined treatment is similar to liposomal doxorubicin, Caelyx®.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.